Holger N. Reithinger

NeurogesX, Inc. developed and commercialized novel pain management therapies. The company was founded by Wendye R. Robbins on May 28, 1998 and was headquartered in San Mateo, CA.

FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction.

Whatman Ltd. develops, manufactures, and markets separation technology used for filtration, purification and storage of chemicals, and other liquids, and samples. The company was founded in 1740 by James Whatman and Ann Harris and is headquartered in Kent, UK.

Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany.

Cellnovo Group SA was a medical technology company, which specialized in diabetes. The company developed and marketed the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. It products portfolio included system, switch, pump therapy, and patient stories. The company was founded by Julian Shapley on December 15, 2014 and was headquartered in Paris, France.

Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany.

Curetis NV engages in the manufacture, research and development, and commercialization of molecular microbiology solutions. It offers unyvero platform, which comprsises of the unyvero system with the A50 analyzer at its core, proprietary software, and single-use, application-specific cartridges. The company was founded by Johannes Bacher, Gerd Luedke and Andreas Boos in August 2007 and is headquartered in Holzgerlingen, Germany.

Cellnovo Ltd. manufactures diabetes management devices. The private company is based in Bridgend, UK. The British company was founded by Julian Shapley. The CEO is Sophie Baratte.

CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany.

Gotham Therapeutics Corp. develops and manufactures pharmaceutical medicines. The firm develops new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. The company was founded by Samie Jaffrey in 2017 and is headquartered in New York, NY.

High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.